Trademark: 87421067
Status Date
Monday, March 29, 2021
Filing Date
Friday, April 21, 2017
Published for Opposition
Tuesday, December 26, 2017
Abandoned Date
Monday, March 29, 2021
1 Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
5 infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens
42 Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network
Mar 29, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 29, 2021
Abandonment - No Use Statement Filed
Aug 12, 2020
Notice Of Approval Of Extension Request E-Mailed
Aug 11, 2020
Extension 5 Granted
Jul 29, 2020
Extension 5 Filed
Aug 10, 2020
Case Assigned To Intent To Use Paralegal
Aug 3, 2020
Case Assigned To Intent To Use Paralegal
Jul 29, 2020
Teas Extension Received
Feb 7, 2020
Notice Of Approval Of Extension Request E-Mailed
Feb 5, 2020
Extension 4 Granted
Feb 5, 2020
Extension 4 Filed
Feb 5, 2020
Teas Extension Received
Jan 30, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 30, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 21, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 21, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 16, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 16, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 22, 2019
Notice Of Approval Of Extension Request E-Mailed
Aug 19, 2019
Extension 3 Granted
Aug 19, 2019
Extension 3 Filed
Aug 19, 2019
Teas Extension Received
Feb 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Feb 15, 2019
Extension 2 Granted
Feb 15, 2019
Extension 2 Filed
Feb 15, 2019
Teas Extension Received
Sep 21, 2018
Notice Of Approval Of Extension Request E-Mailed
Sep 21, 2018
Corrected Noa E-Mailed
Sep 20, 2018
Extension 1 Granted
Aug 20, 2018
Extension 1 Filed
Sep 20, 2018
Divisional Processing Complete
Aug 20, 2018
Divisional Request Received
Sep 17, 2018
Case Assigned To Intent To Use Paralegal
Aug 20, 2018
Teas Request To Divide Received
Aug 20, 2018
Teas Extension Received
Feb 26, 2018
Changes/Corrections After Pub Approval Entered
Feb 20, 2018
Noa E-Mailed - Sou Required From Applicant
Feb 16, 2018
Assigned To Petition Staff
Feb 6, 2018
Teas Post Publication Amendment Received
Dec 26, 2017
Official Gazette Publication Confirmation E-Mailed
Dec 26, 2017
Published For Opposition
Dec 6, 2017
Notification Of Notice Of Publication E-Mailed
Nov 14, 2017
Approved For Pub - Principal Register
Nov 14, 2017
Examiner's Amendment Entered
Nov 14, 2017
Notification Of Examiners Amendment E-Mailed
Nov 14, 2017
Examiners Amendment E-Mailed
Nov 14, 2017
Examiners Amendment -Written
Nov 9, 2017
Teas/Email Correspondence Entered
Nov 8, 2017
Correspondence Received In Law Office
Nov 8, 2017
Teas Response To Office Action Received
Jul 24, 2017
Notification Of Priority Action E-Mailed
Jul 24, 2017
Priority Action E-Mailed
Jul 24, 2017
Priority Action Written
Jul 17, 2017
Assigned To Examiner
Apr 28, 2017
New Application Office Supplied Data Entered In Tram
Apr 25, 2017
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
